MENLO PARK, CA--(Marketwired - April 17, 2014) - TauTona Group, a medical device incubator and investment fund focused on the rapid development of innovative medical products, today announced that its wholly-owned subsidiary Aline Aesthetics has completed the sale of its Aline hyaluronic acid (HA) thread technology to Allergan, Inc. The Aline HA technology is under development for use as a dermal filler.
"We are delighted to announce the sale of our third product, Aline HA, to Allergan," said Geoffrey Gurtner M.D., managing partner at TauTona and professor of plastic surgery at Stanford University.
Aline HA is comprised of a solid state, cross-linked hyaluronic acid in thread form that is attached to a needle.
"We are very pleased to announce TauTona's third exit in recent months," said Dr. Gurtner. "At TauTona we are pursuing a new venture capital model: one that develops the insights of physicians and inventors using a capital efficient process to turn them into commercial products. Our third exit provides an excellent multiple on the invested capital and, in combination with our other exits, will contribute to a strong return for our first fund."
About TauTona Group
TauTona Group is a life-science incubator and investor focused on rapid development of innovative products, with special expertise in surgery, aesthetics and wound care. Co-founded in 2010 by two Stanford School of Medicine surgery professors, TauTona invests in and develops innovative medical devices for commercialization by strategic partners. Recent exits include the sale of the TauTona Tissue Injector to LifeCell, the sale of its Surgical Marker technology to Novadaq® Technologies Inc., (NASDAQ: NVDQ) (TSX VENTURE: NDQ) and the sale of Aline HA® to Allergan, Inc. (NYSE: AGN). TauTona also has several other devices currently under development or in the approval process.
TauTona partners with entrepreneurs, institutions and corporations to fund, develop and build exceptional surgical medical devices using its in-house engineering and business expertise.